Table 2.
Duration of follow up and incidence of MACE in patients with and without ISMN
| All (n = 108 ) | Without ISMN (n = 62) | With ISMN (n = 46 ) | P value | |
|---|---|---|---|---|
| Duration of Follow-up (months) | 25.3 ± 25 | 26.2 ± 10.8 | 24.1 ± 13.5 | 0.39 |
| MACE, n (%) | 16 (14.8) | 4 (6.5) | 12 (26.1) | * < 0.01 |
| Cardiovascular mortality, n (%) | 3 (2.8) | 2 (3.2) | 1 (2.2) | 1.00 |
| Non-fatal myocardial infarction, n (%) | 6 (5.5) | 0 (0) | 6 (13.0) | * < 0.01 |
| In-stent restenosis, n (%) | 7 (6.5) | 2 (3.2) | 5 (10.9) | 0.13 |
| All cause mortality, n (%) | 5 (4.6) | 3 (4.8) | 2 (4.3) | 1.00 |
Abbreviation: Similar to Table 1, MACE: Major adverse cardiovascular events.